about
An in situ pig liver esterase assay as a useful predictive tool for the likely in vitro anti viral activity of phosphoramidate pro-drugsDesign and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSARSynthesis and antiviral activity of acyclovir-5'-(phenyl methoxy alaninyl) phosphate as a possible membrane-soluble nucleotide prodrugPotent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic baseMechanism of anti-HIV action of masked alaninyl d4T-MP derivativesDiscovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of a terminal halogen substitution in the side-chain.The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): the effect of terminal unsaturation in the side chain.INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirinActivation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularineThe application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition.Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy.The journey towards elucidating the anti-HCMV activity of alkylated bicyclic furano pyrimidines.ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents.Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.Evaluation of novel phosphoramidate ProTides of the 2'-fluoro derivatives of a potent anti-varicella zoster virus bicyclic nucleoside analogue.Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743.Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside.Synthesis and biological evaluation of N- and O-alkylated bicyclic furanopyrimidines as non-nucleosidic inhibitors of human cytomegalovirus.Naphthyl phosphoramidate derivatives of BVdU as potential anticancer agents: design, synthesis and biological evaluation.Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin.Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase.Phosphoramidate protides of 2',3'-dideoxy-3'-fluoroadenosine and related nucleosides with potent activity against HIV and HBV.Synthesis of unusual bicyclic nucleosides bearing an unsaturated side-chain, as potential inhibitors of varicella-zoster virus (VZV).Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers.Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain.Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation.Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.Enhanced inhibition of the EDHF phenomenon by a phenyl methoxyalaninyl phosphoramidate derivative of dideoxyadenosineIn vitro delivery of novel, highly potent anti-varicella zoster virus nucleoside analogues to their target site in the skin.
P50
Q28370119-FEB7A745-2787-4C8F-9667-DFAFAF9257FFQ28373848-4D96264C-5D54-4838-B6E5-AEC0EB19B7B6Q28376570-016BE0C9-050E-40D0-8589-1312951270BEQ28377160-87822FAE-75CF-405B-956A-256959B33F16Q28378931-01A8B13C-50AE-4528-92B8-7C6738CEF06EQ30913654-FB542127-D482-4F47-AED0-6D59AACA8A8BQ31398603-E36F72C0-626B-4F84-94CF-3F0FB847A0F3Q31906589-9D8DF2D0-A667-40B6-84CC-E2FAC8D33D72Q32044820-2AEA33C9-5172-4C4B-A207-C7FC37B34F4BQ34933094-CA87FF7A-D162-4093-A68F-49CEFDAF5468Q35174673-A53284C7-E1A0-42C0-96D7-CE7BC2F389B7Q35941302-22E458D5-3F5C-4DF1-935C-026457E05AE7Q37138424-1F755BE3-0EBA-403D-903E-0D3F56C4F627Q37357285-513DC7A0-8823-4393-8CB8-1942F391C05DQ37969861-342E008E-A9BA-442E-BF36-95C3C9B52BE4Q38574832-8D47AE63-5769-4B68-962D-45B2D3617334Q39009427-DBEC396E-C3BD-43C1-A1EC-5A3EFBF2117CQ39029664-9C9278E1-6507-43DE-AB7A-2E12955FCAA6Q39450374-C15131D6-1BEE-4936-AB13-B7D103954AC5Q39487589-A07A68C6-A3B4-4CA9-8B41-AED09A603356Q39636489-BB357941-D993-4B41-B0AC-E0C358D7251FQ39696249-D384042B-461D-4584-A03D-AF7E36ACAB35Q39731455-AB406E97-876D-45F7-8547-1CED04743FA8Q39787012-1CA0AFCD-95BB-46C7-AEC8-DA9944AC9C30Q40157814-D5256D9D-7BD5-48C2-B38D-3C951F7A05CEQ40358213-9E91791D-ACED-4608-8030-67A5C77A8424Q40358218-8B1E4655-2B34-4335-B7F5-E1DEAA79A7CBQ40439082-457ED4CA-6AA4-4D69-BCBF-8A26011A0241Q40522688-FD116C97-47BE-4479-950F-EAA6916AFCC2Q40585710-450601F5-5AE2-443F-8FA7-C64BFB6B58D7Q40618080-FA7BB8EF-2A41-4B37-A748-C961486A4170Q40625262-D158DF39-5274-4F0F-BC22-9057714E3D6AQ40626497-311B8C63-6C83-4560-8BB0-43FE41C48E1FQ40833266-DBFAC4DF-AE6A-446F-958E-0242535989FAQ41091829-86289107-7F4C-414E-959B-7342B604B0D5Q41095937-EBCA6090-4175-40C4-86A0-B8DE9131D524Q41103590-B56827CE-2597-4C5C-8946-E74B0DB8E4BEQ41175526-3D323767-0625-41E1-A201-3FEB0CBE2498Q42258763-F2FDC8F7-F1B3-4CED-8C63-5D1A870AB3A3Q42463608-32DFADA1-A405-4F42-8A97-25CB67D29432
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chris McGuigan
@ast
Chris McGuigan
@en
Chris McGuigan
@es
Chris McGuigan
@nl
Chris McGuigan
@sl
type
label
Chris McGuigan
@ast
Chris McGuigan
@en
Chris McGuigan
@es
Chris McGuigan
@nl
Chris McGuigan
@sl
prefLabel
Chris McGuigan
@ast
Chris McGuigan
@en
Chris McGuigan
@es
Chris McGuigan
@nl
Chris McGuigan
@sl
P1053
P-1580-2014
P106
P1153
7006988377
P31
P3829
P496
0000-0001-8409-710X